• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pharmacology for GAD: Complex Choices

Pharmacology for GAD: Complex Choices

November 15, 2019
Randall Moore, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Randall Moore, MD. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Slee A et al, Lancet 2019;393(10173):768–777


Study Type: Network meta-analysis


With over 2 dozen choices, how do we pick a medication for generalized anxiety disorder (GAD)? The authors of this network meta-analysis sought to answer this question.


Network meta-analysis allows researchers to gauge treatments that haven’t been directly compared in head-to-head studies. If drug A works better than drug B and B works better than C, then the network meta-analysis concludes that A is likely to work better than C, even though A and C have never been directly compared.


The investigators selected 89 trials of 25 drugs studied in over 25,000 patients. The primary outcome was change in the Hamilton Rating Scale for Anxiety (HAM-A). Trial length varied from 4 to 26 weeks.


Surprisingly, quetiapine XR was the most efficacious among the medications with large sample sizes. However, its benefit was modest, with a reduction of 3.6 points on the HAM-A compared to placebo (150–300 mg per night, as monotherapy). Quetiapine XR was poorly tolerated with a high discontinuation rate (odds ratio 1.44). The following drugs were well tolerated and are listed in order of efficacy: duloxetine, pregabalin, venlafaxine XR, and escitalopram.


The 4 benzodiazepines were studied as a class, not as individual drugs. Patients quit benzodiazepines much more often than placebo (odds ratio 1.43), although the reasons for discontinuation were not explored.


Studies were excluded if the patients had psychiatric comorbidities other than depression, which means the subjects might have been significantly less ill than the patients we see in routine practice.


One-third of the trials were not placebo controlled, and a fairly large number of them had limited quality. However, a sensitivity analysis concluded that these deficiencies did not significantly distort the results.


Although the meta-analysis did not analyze the data according to the quality of the studies, dose, or duration of treatment, TCPR has analyzed these issues by drilling down on the appendix and the original studies. The studies of pregabalin were all of lower quality. The studies of duloxetine were of the highest quality, followed by escitalopram and venlafaxine XR. For duloxetine, venlafaxine, and escitalopram, high doses (eg, duloxetine 120 mg) were no more efficacious than medium doses (eg, duloxetine 60 mg). Of these 3 antidepressants, only venlafaxine XR was studied for more than 12 weeks, and those studies demonstrated greater efficacy than shorter studies, suggesting that its benefits may build over time.


TCPR’S TAKE
In GAD, duloxetine stands out for its efficacy, safety, and the quality of its studies. This antidepressant has FDA approval in childhood GAD as well. It may take a few months to see the full effects of antidepressants in GAD, and medium doses are as likely to work as higher ones. Quetiapine XR is one of the more effective medications for GAD, but it has major safety and tolerability issues that caused the FDA to withhold its approval in 2009.



For an in-depth look at generalized anxiety disorder and its cousin, neuroticism, listen to our 4-part podcast series, premiering in November.


Search for “Carlat” on your podcast store.



 

General Psychiatry
KEYWORDS cymbalta duloxetine effexor generalized-anxiety-disorder lyrica pharmacology pregabalin research research-update ssris venlafaxine
    Randall Moore, MD.

    An Answer for Psychotic Depression

    More from this author
    www.thecarlatreport.com
    Issue Date: November 15, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Adult ADHD, TCPR, November/December 2019
    Highlights From This Issue
    Adult-Onset ADHD
    Micronutrients in Mental Health
    Adult ADHD: What Else Could It Be?
    Stimulants as Cognitive Enhancers
    A Practical Guide to Light Therapy
    Meet the First H3 Antagonist
    An Antipsychotic Patch
    Pharmacology for GAD: Complex Choices
    Olanzapine for Anorexia Nervosa
    In Brief: Antipsychotic Update
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.